Advanced bladder cancer: Status of first‐line chemotherapy and the search for active agents in the second‐line setting

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer

• Publication date

  2008-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.23692PMID 18629841
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Statistics, 2008

  2008cited by this paper
• Phase 2 trial of epothilone B analog BMS‐247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800)

  2007cited by this paper
• Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU)

  2007cited by this paper
• 4534 POSTER Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU)

  2007cited by this paper
• Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma

  2007cited by this paper
• Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC)

  2007cited by this paper
• Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.

  2007cited by this paper
• RECIST revisited: a review of validation studies on tumour assessment.

  2006cited by this paper
• Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

  2006cited by this paper
• Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

  2006cited by this paper
• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

  2006cited by this paper
• A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia

  2006cited by this paper
• A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

  2006cited by this paper
• Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102.

  2006influential reference
• A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.

  2005cited by this paper
• Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced HER2-positive urothelial carcinoma: Results of a multi-center phase II NCI trial

  2005cited by this paper
• The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development

  2005cited by this paper
• Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

  2005cited by this paper
• A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract

  2005cited by this paper
• Randomised phase II trial of gemcitabine and paclitaxel second‐line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99)

  2005cited by this paper
• Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo

  2005cited by this paper
• Phase II trial of carboplatin and paclitaxel in cisplatin‐pretreated advanced transitional cell carcinoma

  2005cited by this paper
• A phase II trial of gemcitabine and carboplatin (GC) in patients with transitional cell carcinoma of the urinary tract (TCC).

  2004cited by this paper
• Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.

  2004cited by this paper
• Single-Agent Gemcitabine in Previously Untreated Elderly Patients with Advanced Bladder Carcinoma: Response to Treatment and Correlation with the Comprehensive Geriatric

  2004cited by this paper
• Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

  2004cited by this paper
• CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.

  2004cited by this paper
• FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

  2004cited by this paper
• HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?

  2004cited by this paper
• Overview of bladder cancer trials in the European Organization for Research and Treatment

  2003cited by this paper
• Gemcitabine in transitional cell carcinoma of the urothelium

  2003cited by this paper
• Overview of bladder cancer trials in the European Organization for Research and Treatment

  2003cited by this paper
• Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract

  2003cited by this paper
• Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

  2002cited by this paper
• Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.

  2002cited by this paper
• Gemcitabine Monotherapy as Second-Line Treatment in Cisplatin-Refractory Transitional Cell Carcinoma – Prognostic Factors for Response and Improvement of Quality of Life

  2002cited by this paper
• Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder.

  2002cited by this paper
• Piritrexim in Advanced, Refractory Carcinoma of the Urothelium (E3896): A Phase II Trial of the Eastern Cooperative Oncology Group

  2002cited by this paper
• Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

  2001cited by this paper
• Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer

  2001cited by this paper
• Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer.

  2001cited by this paper
• Chemotherapy with an every‐2‐week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin‐based therapy

  2001cited by this paper
• Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.

  2001cited by this paper
• Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract

  2000cited by this paper
• Phase II Trial of Pyrazoloacridine as Second-Line Therapy for Patients with Unresectable or Metastatic Transitional Cell Carcinoma

  2000cited by this paper
• Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

  2000cited by this paper
• Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.

  1999influential reference
• Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study.

  1999cited by this paper
• A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer.

  1998cited by this paper
• Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid

  1998cited by this paper
• Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.

  1998cited by this paper
• Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial

  1998cited by this paper
• A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum

  1998cited by this paper
• Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma.

  1997cited by this paper
• Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1997cited by this paper
• Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.

  1997cited by this paper
• The treated natural history of high risk superficial bladder cancer: 15-year outcome.

  1997cited by this paper
• Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.

  1997cited by this paper
• Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.

  1997cited by this paper
• Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.

  1997cited by this paper
• Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis.

  1995influential reference
• Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study.

  1994cited by this paper
• Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial

  1994cited by this paper
• Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin‐based chemotherapy

  1992cited by this paper
• A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1992cited by this paper
• A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1992cited by this paper
• A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

  1990cited by this paper
• Cancer statistics

  1989cited by this paper
• Chemotherapy in the Management of Bladder Tumours

  1989cited by this paper
• Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder.

  1987cited by this paper
• Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

  1985cited by this paper
• Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.

  1985cited by this paper
• Progress in treatment of advanced urothelial tract tumors.

  1985cited by this paper
• Metastases from transitional cell carcinoma of urinary bladder.

  1980cited by this paper

• Outcomes of Surgical Therapy for Local Recurrence and Oligometastatic Urothelial Carcinoma of the Bladder: 20 Years of Experience in a Tertiary Center

  2024cites this paper
• BMI1 activates P-glycoprotein via transcription repression of miR-3682-3p and enhances chemoresistance of bladder cancer cell

  2021cites this paper
• Immunohistochemical expression of receptors for luteinizing hormone-releasing hormone (LHRHR) in muscle-invasive Urothelial carcinoma of urinary bladder: a potential predictive marker for targeted cytotoxic LHRH hybrid analogs

  2020cites this paper
• Suppression of HAX-1 induced by miR-325 resensitizes bladder cancer cells to cisplatin-induced apoptosis.

  2020cites this paper
• Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1/ERβ/Bcl-2 signalling

  2019cites this paper
• The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)

  2019cites this paper
• Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

  2019cites this paper
• Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial

  2019cites this paper
• A place for precision medicine in bladder cancer: targeting the FGF receptors

  2018cites this paper
• Platinum drugs, copper transporters and copper chelators

  2018cites this paper
• Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease

  2018cites this paper
• Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy

  2018cites this paper
• Survival after Metastasectomy for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis

  2017cites this paper
• Kavalactone yangonin induces autophagy and sensitizes bladder cancer cells to flavokawain A and docetaxel via inhibition of the mTOR pathway

  2017cites this paper
• Real‐world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio

  2017cites this paper
• Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy

  2016cites this paper
• Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.

  2016cites this paper
• Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience

  2016cites this paper
• A place for precision medicine in bladder cancer: targeting the FGFRs.

  2016cites this paper
• Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: long-term efficacy and implications for trial design.

  2015cites this paper
• Targeting the VEGF pathway in metastatic bladder cancer

  2015cites this paper
• Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis.

  2015cites this paper
• Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.

  2014cites this paper
• Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma.

  2014cites this paper
• The Epigenetically Regulated Effects of Wnt Antagonists on the Expression of Genes in the Apoptosis Pathway in Human Bladder Cancer Cell Line (T24)

  2014cites this paper
• Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.

  2014cites this paper
• Single Case of a Complete Response in a Metastatic Urothelial Carcinoma Patient Treated with Zoptarelin Doxorubicin

  2014cites this paper
• Sunitinib malate in the treatment of urothelial cancer

  2014cites this paper
• No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine.

  2013cites this paper
• A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder.

  2013cites this paper
• Genetic Instability in Normal-Appearing and Tumor Urothelium Cells and the Role of the TP53 Gene in the Toxicogenomic Effects of Antineoplastic Drugs

  2013cites this paper
• Phase II study of everolimus in metastatic urothelial cancer

  2013cites this paper
• Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy

  2013influential citation
• Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

  2012cites this paper
• Cytogenetic profile of locally advanced and metastatic Schistosoma-related bladder cancer and response to chemotherapy.

  2012cites this paper
• Vinflunine

  2012cites this paper
• Vinflunine: a guide to its use in bladder cancer

  2012cites this paper
• The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers

  2011cites this paper
• 5-azacytidine reverses drug resistance in bladder cancer cells.

  2011cites this paper
• Hypoxia‐inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications

  2011cites this paper
• Subamolide A, a component isolated from Cinnamomum subavenium, induces apoptosis mediated by mitochondria-dependent, p53 and ERK1/2 pathways in human urothelial carcinoma cell line NTUB1.

  2011cites this paper
• Overview of SLC22A and SLCO families of drug uptake transporters in the context of cancer treatments.

  2011cites this paper
• Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents.

  2011cites this paper
• Chemotherapeutic Agents for Urologic Oncology

  2011cites this paper
• Curcumin-Induced Mitotic Spindle Defect and Cell Cycle Arrest in Human Bladder Cancer Cells Occurs Partly through Inhibition of Aurora A

  2011cites this paper
• Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder

  2011cites this paper
• Structural requirement of arylindolylpropenones as anti-bladder carcinoma cells agents.

  2011cites this paper
• Chemotherapy for Metastatic Bladder Cancer

  2011cites this paper
• Genome‐wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage

  2010cites this paper
• Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy

  2010cites this paper
• Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise

  2010cites this paper
• Multifactorial, site‐specific recurrence model after radical cystectomy for urothelial carcinoma

  2010cites this paper
• Novel strategies for treating relapsed/refractory urothelial carcinoma

  2010cites this paper
• Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

  2010cites this paper
• Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine

  2010cites this paper
• Bladder Cancer in 2010: How Far have We Come?

  2010cites this paper
• Second-line therapy in bladder cancer

  2009cites this paper
• Morphological Analysis of Pancreatic Adenocarcinoma on Multidetector Row Computed Tomography: Implications for Treatment Response Evaluation

  2009cites this paper
• Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis.

  2009cites this paper
• Current World Literature

  2009cites this paper
• Phase 2 trial of sorafenib in patients with advanced urothelial cancer

  2009cites this paper
• Development of novel agents for bladder cancer

  2009cites this paper
• Evidence Review Group Report commissioned by the NHS R&D HTA Programme on behalf of NICE

  2009cites this paper
• Monoclonal antibody therapies for solid tumors

  2009cites this paper
• A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma

  2009cites this paper
• Neue regionale Therapieansätze bei Leber-, Lungenmetastasen und derPeritonealkarzinose

  2009cites this paper
• Investigation of a new 1,3-diarylpropenone as a potential antimitotic agent targeting bladder carcinoma

  2009cites this paper
• Molecular targets and targeted therapies in bladder cancer management

  2008cites this paper
• Advanced bladder cancer: So many drugs, so little progress

  2008cites this paper
• -(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro.

  2008cites this paper
• What’s Wrong with this Picture?

  1985cites this paper